VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized (spread to other parts of the body). It is administered ...

CDK4/6 inhibitor Verzenio (abemaciclib) was the third drug in the class to reach the market, first approved in 2017 as a second-line treatment for post-menopausal patients with hormone receptor ...

Pharmaceutical manufacturers are padding their wallets while rural families and retirees are squeezed by a system designed to benefit shareholders, not patients,” writes Tonja Hanson in an op-ed.

Its fourth-quarter revenue not related to GLP-1 drugs grew by 20% year over year. Sales of Verzenio, a targeted breast-cancer therapy grew 36% year over year to an annualized $6.2 billion.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | Presiding over the upward trajectory of Eli Lilly over the last eight years is ...

The drug is a non-chemotherapy oral tablet. The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of VERZENIO. The report also ...

VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized (spread to other parts of the body). It is administered ...